Companies in CRISPR

Celgene is selling part of its share in CRISPR Therapeutics.


From FiercePharma:




Bill Lundberg, M.D., has stepped down as CSO of CRISPR Therapeutics. News of Lundberg’s departure emerged on the same day
Celgene revealed it has sold another chunk of its once-double-digit stake in the CRISPR/Cas9 gene editing startup.

Lundberg landed at CRISPR in 2015 with a brief to lead the establishment of its R&D operation. With the Cambridge, MA
facility ticking over and the most advanced candidates developed at the site on the cusp of the clinic,
Lundeberg is moving on. Lundberg’s departure is immediate but the ex-Alexion VP will continue to help CRISPR as a senior advisor and as head of its scientific advisory board.

The departure leaves CRISPR without a CSO. In the absence of Lundberg, Tony Ho, M.D., will oversee CRISPR’s R&D activities.
CRISPR appointed Ho, who previously worked at AstraZeneca and Merck, as its head of R&D in August. Ho inherits a broad
preclinical pipeline of ex vivo and in vivo CRISPR/Cas9 programs CRISPR hopes will quell doubts about whether the technology is ready for prime time.



link: https://www.fiercebiotech.com/biotech/crispr-cso-departs-as-celgene-continues-to-sell-stock.


Delgene has a tie-in to Editas:



Editas is partnering with Juno Therapeutics, which was acquired by Celgene earlier this year, on use of CRISPR
to engineer T cells for treating cancer. The company thinks its technology could significantly expand the types of cancer that can be treated by CAR-T.


Taken from Motley Fool, https://www.fool.com/investing/2018/05/01/top-gene-editing-stocks-for-long-term-investors.aspx